Health Care [ 6/12 ] | Biotechnology [ 38/74 ]
NASDAQ | Common Stock
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases.
It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA); and Apellis Assist, a patient-focused program specifically designed to assist patients with onboarding, product training and ongoing support with pegcetacoplan treatment, and built a care educator team to connect directly with PNH patients and their caregivers to provide education and training on the use of pegcetacoplan.
The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development.
It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases.
The company was incorporated in 2009 and is based in Waltham, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 25, 25 | -0.29 Increased by +60.27% | -0.40 Increased by +27.84% |
| Nov 5, 24 | -0.46 Increased by +60.48% | -0.30 Decreased by -54.13% |
| Aug 1, 24 | -0.28 Increased by +72.55% | -0.32 Increased by +12.50% |
| May 7, 24 | -0.42 Increased by +73.08% | -0.47 Increased by +10.64% |
| Feb 27, 24 | -0.73 Increased by +51.33% | -0.69 Decreased by -5.80% |
| Nov 1, 23 | -1.17 Increased by +33.14% | -0.86 Decreased by -36.05% |
| Jul 31, 23 | -1.02 Increased by +30.14% | -1.32 Increased by +22.73% |
| May 4, 23 | -1.56 Decreased by -9.86% | -1.46 Decreased by -6.85% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 212.53 M Increased by +45.19% | -36.35 M Increased by +58.96% | Decreased by -17.11% Increased by +71.73% |
| Sep 30, 24 | 196.83 M Increased by +98.45% | -57.45 M Increased by +59.04% | Decreased by -29.19% Increased by +79.36% |
| Jun 30, 24 | 199.69 M Increased by +110.26% | -37.66 M Increased by +69.14% | Decreased by -18.86% Increased by +85.32% |
| Mar 31, 24 | 172.32 M Increased by +284.26% | -66.42 M Increased by +62.64% | Decreased by -38.55% Increased by +90.28% |
| Dec 31, 23 | 146.38 M Increased by +545.89% | -88.58 M Increased by +46.64% | Decreased by -60.51% Increased by +91.74% |
| Sep 30, 23 | 99.18 M Increased by +349.68% | -140.24 M Increased by +26.68% | Decreased by -141.39% Increased by +83.70% |
| Jun 30, 23 | 94.97 M Increased by +481.85% | -122.04 M Increased by +21.76% | Decreased by -128.50% Increased by +86.55% |
| Mar 31, 23 | 44.85 M Increased by +211.84% | -177.78 M Decreased by -27.96% | Decreased by -396.42% Increased by +58.97% |